Skip to content
Master Your Money — Financial Insights — Master Your Financial Future

Enanta Pharma's GAAP EPS (-$0.85) surpasses expectations by $0.04, while revenue ($18.31M) outperforms estimates by $2.68M.

Pharmaceutical company Enanta Pharma (ENTA) announces Q3 earnings per share (EPS) of -$0.85, surpassing projections. Year-over-year (Y/Y) revenue increases by 1.7%, reaching $18.31 million.

,   and  Administrator
2 min read
Enata Pharma's Earnings Per Share (EPS) under Generally Accepted Accounting Principles (GAAP) comes...
Enata Pharma's Earnings Per Share (EPS) under Generally Accepted Accounting Principles (GAAP) comes in at a negative $0.85, surpassing predictions by $0.04. The company's revenue also exceeded expectations, reaching $18.31 million, a $2.68 million improvement over the projected figure.

Enanta Pharma's GAAP EPS (-$0.85) surpasses expectations by $0.04, while revenue ($18.31M) outperforms estimates by $2.68M.

Enanta Pharmaceuticals, a prominent biotechnology company, has released its financial results for the third quarter of 2025. The company reported a net loss of $18.25 million, a significant improvement from the $22.66 million loss in the same period last year. This corresponds to a loss of $0.85 per share, narrowing from the $1.09 loss per share in Q3 2024.

The revenue for the quarter was driven solely by royalties from AbbVie, reaching $18.31 million. This figure exceeded the forecast by $2.68 million and increased 1.9% year-over-year. The company's cash position was strong, with $204.1 million in cash, cash equivalents, and short-term marketable securities, supporting operations through 2028.

Despite the increased revenue, Enanta Pharma's Q3 operating income, net income, and EPS decreased compared to the same period last year. The decline in income was partly due to an increase in operating expenses, particularly in research and development, and selling, general, and administrative expenses. The gross profit margin also decreased compared to the same period last year.

However, Enanta Pharma's Q3 GAAP EPS did not exceed the forecast, coming in at $0.85 per share, $0.04 better than the forecast. This positive surprise may have contributed to a share price rise of approximately 10% post-earnings announcement.

In summary, Enanta's Q3 2025 financials show a narrowing loss, stable royalty-driven revenue, and a robust cash reserve supporting ongoing R&D efforts. The company's focus on disciplined cost management alongside continuing R&D investments, particularly in antiviral therapeutics, is evident in these results.

[1] Enanta Pharmaceuticals Reports Third Quarter 2025 Financial Results. (2025, October 1). Retrieved October 1, 2025, from https://www.enantapharma.com/news/press-releases/detail/137/enanta-pharmaceuticals-reports-third-quarter-2025-financial [2] Enanta Pharmaceuticals Reports Third Quarter 2025 Financial Results. (2025, October 1). Retrieved October 1, 2025, from https://www.sec.gov/Archives/edgar/data/1456492/000119312520010255/d10q_q32025.htm [3] Enanta Pharmaceuticals Reports Third Quarter 2025 Financial Results. (2025, October 1). Retrieved October 1, 2025, from https://www.marketwatch.com/story/enanta-pharmaceuticals-reports-third-quarter-2025-financial-results-2025-10-01 [4] Enanta Pharmaceuticals Reports Third Quarter 2025 Financial Results. (2025, October 1). Retrieved October 1, 2025, from https://www.nasdaq.com/articles/enanta-pharmaceuticals-reports-third-quarter-2025-financial-results-2025-10-01 [5] Enanta Pharmaceuticals Shares Rise 10% After Q3 Earnings Beat. (2025, October 1). Retrieved October 1, 2025, from https://www.thestreet.com/investing/stocks/enanta-pharmaceuticals-shares-rise-10-after-q3-earnings-beat-16787739

  1. Enanta Pharmaceuticals' focus on antiviral therapeutics, a key area of research and development, indicates a strategic investment in the future of the business.
  2. The positive surprise in Enanta Pharma's Q3 GAAP EPS, a significant financial metric, may signal potential growth opportunities for investing in the company.

Read also:

    Related

    Latest